Friday, October 09, 2020 10:33:40 AM
IMT504 has been granted orphan drug status & qualifies for FDA Tropical Disease Priority Review Voucher (PRV) Program.
In 2016–2018, the value of a voucher ranged from $125 million to $200 million.
http://www.globenewswire.com/news-release/2020/10/09/2106348/0/en/Connectyx-Technologies-Holdings-Group-Inc-Announces-Definitive-Agreement-with-Mid-Atlantic-BioTherapeutics-Inc-for-Treatment-of-Symptomatic-Rabies.html
Recent CUBT News
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 05/06/2024 09:31:41 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM